Analysts Anticipate Ophthotech Corp (OPHT) to Announce -$0.36 EPS

Equities research analysts expect Ophthotech Corp (NASDAQ:OPHT) to report earnings of ($0.36) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Ophthotech’s earnings. Ophthotech also posted earnings per share of ($0.36) during the same quarter last year. The company is scheduled to issue its next quarterly earnings report on Wednesday, May 8th.

According to Zacks, analysts expect that Ophthotech will report full year earnings of ($1.21) per share for the current financial year, with EPS estimates ranging from ($1.26) to ($1.16). For the next year, analysts anticipate that the firm will report earnings of ($1.43) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Ophthotech.

Several equities analysts have commented on OPHT shares. Zacks Investment Research reaffirmed a “hold” rating on shares of Ophthotech in a research report on Monday, December 31st. ValuEngine downgraded Ophthotech from a “hold” rating to a “sell” rating in a research report on Wednesday, December 12th.

NASDAQ:OPHT opened at $1.42 on Tuesday. The firm has a market cap of $58.40 million, a P/E ratio of -0.85 and a beta of 1.49. Ophthotech has a fifty-two week low of $1.02 and a fifty-two week high of $4.50.

A number of institutional investors have recently made changes to their positions in OPHT. Northern Trust Corp grew its position in Ophthotech by 16.9% in the 4th quarter. Northern Trust Corp now owns 87,029 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 12,594 shares during the last quarter. Two Sigma Investments LP grew its position in Ophthotech by 109.3% in the 4th quarter. Two Sigma Investments LP now owns 173,134 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 90,396 shares during the last quarter. Municipal Employees Retirement System of Michigan bought a new position in Ophthotech in the 4th quarter valued at $460,000. Bridgeway Capital Management Inc. grew its position in Ophthotech by 93.1% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 217,400 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 104,800 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Ophthotech by 19.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 881,887 shares of the biopharmaceutical company’s stock valued at $2,081,000 after acquiring an additional 141,900 shares during the last quarter. 45.39% of the stock is currently owned by institutional investors.

About Ophthotech

Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula.

See Also: Investing in Blue-Chip Stocks

Get a free copy of the Zacks research report on Ophthotech (OPHT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.